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Introduction
G protein-coupled receptors (GPCRs) represent one of the 
largest protein superfamilies and are the site of action for over 
30% of drugs on the market. Traditionally GPCRs have been 
considered targets for small molecule drugs, however their 
development has been hampered by difficulties identifying 
molecules with suitable selectivity and drug-like properties.1 Many 
GPCRs belong to subfamilies with conserved ligand binding sites 
such that the identification of highly selective molecules can be 
difficult. Many small-molecule compounds derived from high 
throughput screening approaches have high lipophilicity and 
molecular weight leading to an increased probability of off-target 
toxicity.2 An alternative approach to GPCR drug discovery is to 
identify functional antibodies that selectively activate or inhibit 
GPCRs of interest. There are increasing efforts to discover and 
develop anti-GPCR antibodies as therapeutics to exploit the wide 
range of disease areas covered by this receptor class.3,4 Antibodies 
not only offer the desired selectivity, but good affinity and 
improved serum half-life. Global sales of therapeutic antibody 
products were in excess of $US 64 billion in 2012 (http://www.
pipelinereview.com/index.php/2013050850905/FREE-Reports/
Blockbuster-Biologics-2012.html), with over 35 of these drugs 
approved by the FDA, and ~350 monoclonal antibodies (mAbs) 
under evaluation in the clinical pipeline.5 Despite a growing 
interest in the use of antibodies as therapeutics, as exemplified 
by the success of mAbs targeting growth factors and receptor 
tyrosine kinases,6 few antibodies directed at GPCRs have 
progressed as therapeutic agents.
Historically, the generation of antibodies against GPCRs 
has been associated with technical hurdles arising from the 
quality and quantity of available antigen,7 e.g., maintaining 
a pure, homogeneous form relevant to the native receptor 
structure, epitope exposure, low receptor cell surface density, 
detergent solubilisation, maintaining epitopes and functional 
activity. Antibodies are able to recognize, bind to and therefore 
stabilize different conformations, as demonstrated by a panel of 
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thermostabilized G protein-coupled receptors used as antigens for in vivo immunization have resulted in the 
generation of functional agonistic anti-β1-adrenergic (β1AR) receptor monoclonal antibodies (mAbs). the focus of this 
study was to examine the pharmacology of these antibodies to evaluate their mechanistic activity at β1AR. Immunization 
with the β1AR stabilized receptor yielded five stable hybridoma clones, four of which expressed functional IgG, as 
determined in cell-based assays used to evaluate cAMp stimulation. the antibodies bind diverse epitopes associated 
with low nanomolar agonist activity at β1AR, and they appeared to show some degree of biased signaling as they were 
inactive in an assay measuring signaling through β-arrestin. In vitro characterization also verified different antibody-
receptor interactions reflecting the different epitopes on the extracellular surface of β1AR to which the mAbs bind. the 
anti-β1AR mAbs only demonstrated agonist activity when in dimeric antibody format, but not as the monomeric Fab 
format, suggesting that agonist activation may be mediated through promoting receptor dimerization. Finally, we have 
also shown that at least one of these antibodies exhibits in vivo functional activity at a therapeutically-relevant dose 
producing an increase in heart rate consistent with β1AR agonism.
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anti-CXCR4 antibodies that seem to recognize different 
conformations of receptor populations dependent on the type of 
host cell.8,9
Immunogens generated to represent GPCRs have covered a 
range of formats and sources, such as peptides corresponding to 
extracellular domains (ECDs), but the majority of antibodies 
obtained via this route react only with the immunizing peptides 
and not with native cell-expressed receptor. Where success has 
been achieved, the antibody has tended to be against a peptide 
receptor and acts by blocking the ligand/receptor interaction. 
Whole cell antigens and membrane preparations have also 
been used for in vivo in immunization as well as in vitro 
approaches, such as phage display (US2006/0275288). Virus-
like particles,10 liposomes,11 nanodiscs,12 exosomes13 and dendritic 
cell immunization14 are examples of other emerging routes for 
producing physiologically-relevant antigen.
Thermostabilization of GPCRs involves the introduction 
of point mutations that stabilize the receptor in a selected 
conformation.15 This method allows extraction of correctly 
folded protein from the cell membrane and purification in 
detergent. The approach was initially developed to assist in 
the crystallization of GPCRs to generate structures of the 
β
1
AR and the adenosine A
2A
 receptor.16,17 The development of 
this technique to produce stabilized receptors (StaR proteins) 
allows large scale purification of stable protein that can be used 
for antibody generation. Stabilizing mutations are chosen such 
that they avoid the extracellular domains that may contribute to 
antibody binding sites.
At least 12 GPCRs are known to involve anti-receptor 
autoantibodies in immune-mediated disease.18 For example, the 
hypoparathyroidism found in both autoimmune polyendocrine 
syndrome type 119 and Sjögren’s syndrome20 is caused by 
autoantibodies directed to the calcium-sensing receptor, and 
autoantibody activation of the thyroid stimulating hormone 
receptor occurs in Graves’ disease.21 It is thought that a number 
of these autoantibodies recognize an immunodominant epitope 
located on the second extracellular loop (ECL2). Consequently, 
substantial interest is growing in the potential of autoantibodies for 
their use in biomarker research and diagnostics, as exemplified by 
the presence of agonist autoantibodies against type 1 angiotensin 
II receptor in ovarian cancer, as well as their possible role in 
angiogenesis and metastasis.22 A review of agonist autoantibodies 
to β-adrenergic receptors and muscarinic M2 receptors23 suggests 
altered receptor conformation and function, allosteric agonism, 
and stabilization of oligomerization as potential mechanisms of 
action.
Figure 1. FACS histogram profiles of mAbs where each hybridoma supernatant binding profile (A–E) was confirmed by detection with anti-mouse pe 
conjugate where binding to HeK293 cells overexpressing β1AR StaR is depicted by the green trace, background binding to untransfected cells is shown 
by the red trace and detection of the Nt tag confirming expression is shown by the blue trace. (F) Specific binding of mAbs to β1AR Star protein was con-
firmed by eLISA where Nunc Immobiliser plates were coated with 5µg/well β1AR StaR protein and incubated with 1µg/ml antibody. this was compared 
with the binding of the mAb panel against closely related stabilized receptors, such as the adenosine A1 StaR and adenosine A2A StaR vs. an irrelevant 
His-tagged receptor StaR (orexin 1). Bound IgG was detected with anti-mouse secondary HRp conjugate and tMB substrate. Absorbance was read at 655 
nm. the mean of triplicate data points was plotted. (G) western blot analysis of mAbs binding to denatured β1AR to determine conformational sensitiv-
ity. β1AR StaR protein was electrophoresed under reducing conditions prior to western blot transfer. two independent blots were prepared as indicated 
by the vertical dotted line. Lanes were probed as follows: Lane 1) MAb3; Lane 2) MAb1; Lane 3) MAb2; Lane 4) MAb5; Lane 5) MAb4; Lane 6) MAb5 and 
Lane 7) Anti-His. Bound antibody was detected by using an anti-mouse HRp conjugate and the eCL detection system (pierce). Sizes in kDa are indicated 
on the either side of the figure.
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To investigate how stabilized receptors could be used to 
generate antibodies, we selected the β
1
AR StaR because this 
presents the challenge of a non-peptide receptor with a limited 
extracellular surface and it is a well-characterized GPCR with a 
published crystal structure and established assays. The purpose 
of this study was 2-fold: first, to demonstrate that stabilized 
receptors are amenable to the generation of functional antibodies, 
and second to examine the physical and pharmacological 
properties of the resulting antibodies to gain further insight as 
to their mechanistic activity and interactions involved in β
1
AR 
signaling.
Results
Antibody generation and characterization
cDNA immunization followed by protein boosting 
was the only immunization strategy advanced to in-depth 
characterization beyond analysis of the binding properties of 
the resulting stable hybridomas; we did evaluate hybridomas 
generated by protein immunization in the cAMP assay, but could 
not detect any agonist mAbs that were of particular interest for 
studying receptor signaling. In addition, we previously tried 
immunizing with wild type (WT) protein, but no immune 
response was detected. Historically, as described in the literature, 
DNA immunization with WT (GPCR) receptor DNA has raised 
a polyclonal response, but this has not been sufficiently robust 
to generate stable hybridomas24 and the authors subsequently 
went on to evaluate the effect of an adjuvant on the genetic 
immunization process to increase the success of identifying 
stable antibody-secreting hybridomas.25 Hence, our strategy 
was to prioritise the DNA prime + protein boost protocol and 
characterize the antibodies generated from this approach to gain 
further understanding of β
1
AR signaling and function.
The scale of effort implemented to generate antibodies to β
1
AR 
was that of a pilot study rather than that of a full therapeutic 
campaign. The immunization strategy implemented in this study 
identified five stable IgG-producing hybridoma clones (MAb1–
5) from 1000 clones that were generated from one fusion using 
standard hybridoma methodology. Flow cytometry analysis using 
labeled antibodies demonstrated that all five mAbs were able to 
bind specifically to HEK293T cells transiently transfected with 
the β
1
AR StaR (Fig. 1A–E), which demonstrated good levels of 
expression, and no background binding of the mAbs was detected 
on HEK293T cells transfected with an irrelevant cDNA.
Overexpression of WT receptor is difficult to achieve for 
many GPCRs as they can internalise or result in cell toxicity 
(the same is seen with ion channels). We have often observed 
that stabilized receptors are better tolerated when overexpressed, 
hence we evaluated binding to cells expressing the StaR and used 
a functional assay for the next step in the screening cascade. 
This can be considered an alternative method to assess antibody 
binding to WT receptor as functional binding assays utilize the 
WT receptor, and this approach is similar to that conducted 
for small molecule discovery. This is because the StaR platform 
provides a means to alter the equilibrium of conformations 
for a given GPCR, therefore an antibody will still bind to the 
corresponding WT receptor because the StaR conformation 
is identical to one of the WT conformations presented at the 
surface of the cell. In addition, all mAbs demonstrated specific 
binding to the purified turkey β
1
AR StaR as displayed in the 
specificity ELISA (Fig. 1F) compared with StaR proteins of 
closely related receptors (adenosine A
1
 and A
2A
 receptors), as well 
as a more distantly related peptide receptor (Orexin, OX1). This 
data also showed that the mAbs were specific for β
1
AR receptor 
protein and not the tag (which was detectable on all StaR protein 
preparations by using an anti-HIS antibody).
Antibody binding was also interrogated using western blot 
analysis to determine whether the antibodies bound to linear 
epitopes since the receptor protein is presented in a denatured 
format in this assay. At least three of the antibodies tested were 
positive in the western blotting assay, indicating that they bound 
to a linear sequence not altered by detergent treatment of the 
protein (Fig. 1G). The apparent molecular weight of the major 
band observed was ~25kDa, which correctly corresponds to the 
size of the C-terminally truncated β
1
AR StaR.15 In contrast, 
MAb1 did not bind to the denatured protein, suggesting that 
it may be conformationally sensitive. Although MAb2 and 
MAb5 were not our focus in the study, the data indicates these 
antibodies do not bind to a linear epitope presented on any of 
the ECL peptides. However, neither antibody appears to be 
conformationally sensitive (positive in Western analysis), so they 
most likely bind to a discontinuous linear epitope that is distinct 
from that recognized by MAb1. This discontinuous epitope 
could represent a close association of two or more ECLs that is 
disrupted on denaturation.
The antibody isotype of the mAbs was determined by ELISA 
(at Aldevron Freiburg) revealing that 4 (MAbs1, 3, 4 and 5) 
were the murine IgG
1
 isotype, whereas MAb2 was the IgG
2b
 
isotype. These isotypes are characteristically produced as the 
predominant isotype in intradermal challenges and are indicative 
of a Th2 response, i.e., where Th2 cells have activated B cells in 
developing an antibody-mediated immune response.
Assessment of diversity
Epitope binning using surface plasmon resonance
Epitope binning using competition pair-wise analysis by 
Biacore was used to determine the number of different epitopes 
to which the mAb panel bound, thus providing an indication 
of diversity. All antibody permutations were analyzed, including 
the injection of two identical antibodies as a control. When the 
second antibody produced a response, we concluded that the two 
antibodies targeted different epitopes, and vice versa. Figure 2A, 
which shows a typical sensorgram where antibodies target 
different epitopes, presents this principle. Results obtained for 
MAbs2 to 4 are shown in Figure 2B and indicate that MAb3 and 
MAb4 target the same epitope that is different from that targeted 
by MAb2. Subsequent analysis also revealed that MAb1 binds 
to an epitope distinct from the previous two (data not shown), 
indicating that three different epitopes were targeted by the four 
mAbs.
Antigen-binding fragments (Fabs) were generated from 
MAb3 to investigate if MAb3 and MAb4 could sterically impede 
the other from binding or if they were competing for the same 
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Figure 2. (A) Surface plasmon resonance and the the principle of epitope binning. this depicts a typical sensorgram (in red) showing two antibodies 
targeting different epitopes. the first increase in RU equates to immobilisation of the antigen to the Biacore chip. the first antibody (Ab1) is then bound 
resulting in a further increase in RU. this is followed by flowing the second antibody (Ab2) through as analyte. An increase in RU indicates that the two 
antibodies bind to two different epitopes. (B) Competition pair-wise analysis: epitope mapping sensorgrams for antibody pairs 2–3, 2–4 and 3–4 by 
using SpR analysis. An increase in RU, as seen in Figure 3A, indicates that the two antibodies bind to two different epitopes (green check), for example, 
MAb2-MAb3, MAb2-MAb4, MAb4-MAb2. Whereas no increase (red x) shows the two antibodies bind to the same epitope, for example, MAb3-MAb4. 
As expected, repeat injection of the same antibody did not produce any additional response, for example, MAb2-MAb2. (C) epitope mapping using a 
crude form of peptide mapping was performed to interrogate the diversity of these mAbs further. peptides corresponding to each extracellular domain 
(eCL1, eCL2, eCL3 and Nt) were synthesized and immobilised to a maleimide-activated surface via a C-terminal cysteine residue. Binding profiles were 
elucidated by eLISA revealing that MAb3 and MAb4 both map to eCL2 and verified our observations from the epitope binning, where both appear to 
bind to the same epitope on β1AR. Specific binding was detected using an anti-mouse HRp conjugate which yielded a minimal amount of background 
binding (anti-mo). (D) β1AR eLISA to demonstrate that binding of MAb3 and MAb4 to recombinant β1AR StaR protein can be blocked by pre-incubation 
of each antibody with the eCL2 peptide in a concentration-dependent manner. (E) Restriction fragmentation with NlaIV to demonstrate antibody gene 
diversity in mAb VH region where each mAb is shown in Lanes 1–4 alongside a 100bp DNA marker in Lane 5.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 N
ott
ing
ha
m]
 at
 07
:21
 21
 Ju
ly 
20
16
 
250 mAbs Volume 6 Issue 1
epitope (or overlapping epitope). No increase in response was 
detected, indicating that these antibodies compete for the same 
epitope (data not shown) rather than one impeding the other 
from binding because of steric hindrance due to the size of the 
dimeric molecule. This could be because these two antibodies are 
identical clones.
 Peptide mapping
MAb3 and MAb4 map to the same epitope as determined 
by the Biacore-based epitope binning, and the data obtained 
by peptide ELISA (Fig. 2C) suggests that this epitope is an 
amino sequence presented on ECL2. However, it has not been 
determined from this analysis if the epitope is positioned in the 
proximal (ECL2a) or distal (ECL2b) domain of this receptor 
loop, where the first Cys residue in ECL2 is thought to form 
a disulfide bridge with the second Cys residue in this sequence 
and the third Cys residue forming a disulfide bridge with a Cys 
residue close to the membrane in TM3 in the expressed receptor. 
MAb2 does not appear to recognize a linear epitope represented 
on any of the peptide sequences for the ECLs
No other interactions with the extracellular loops or N 
terminus were detected. When the same peptides are pre-bound 
to these mAbs, they block MAb3 and MAb4 from binding 
to recombinant β
1
AR protein (Fig. 2D) in a concentration-
dependent manner. Thus, another indication of the diversity 
of functional anti-β
1
AR mAbs is provided by the number of 
different epitopes identified from the epitope binning and 
peptide analysis.
 Restriction digestion of V
H
 regions to evaluate diversity
Due to commercial reasons, we are unable to disclose the V
H
 
and V
L
 region sequences. However, it was possible to demonstrate 
diversity by the alternative method of DNA fragmentation using 
a restriction enzyme that digests with high frequency, such as 
NlaIV. Separation of the resulting restriction fragments for each 
clone can be observed in Figure 2E. The pattern for MAb1 and 
MAb2 is very similar, although MAb1 appears to have a number 
of smaller fragments, but this could be due to a loading difference 
between samples. Nevertheless, as MAb1 and MAb2 bind to 
different epitopes, it can be concluded that these represent 
different clones. On the other hand, MAb3 and MAb4 bind to 
the same epitope and could therefore be identical, however their 
restriction profiles are very different. By combining the epitope 
mapping with this analysis, it can be concluded that all four 
mAbs represent different clones.
Effects of the β
1
AR mAbs on G protein mediated signaling
A preliminary assessment for pharmacological properties 
revealed all four mAbs stimulated cAMP production with EC
50
 
values in the range 0.1–10 nM compared with the isoprenaline 
EC
50
, which was 40 nM ± 22 (Fig. 3A). MAb1 (EC
50 
=  0.1 nM 
± 0.07), MAb3 (EC
50 
=  0.41nM ± 0.25) and MAb4 (EC
50 =
 
0.03nM ± 0.018) demonstrated agonist activity, although this was 
only 86%, 73% and 48% (respectively) of the maximal response 
obtained with isoprenaline. MAb2 (EC
50 =
  9.9 nM ± 0.44 nM) 
stimulated cAMP production at a lower efficacy than the other 
mAbs. One mAb (MAb5), which showed potent binding in the 
ELISA and FACS assays, had no effect in the functional assays. 
Repeat experiments gave EC
50
 values in the range of 0.5–1.5 nM 
for MAbs1–4. The anti-FLAG mAb negative control gave no 
response as expected.
The concentration response curves for the mAbs in the 
Hit Hunter cAMP assay were shifted to the right by the β
1
AR 
antagonist propranolol by varying degrees, confirming that the 
effect in functional assays was mediated by the β
1
AR. A very low 
level of stimulation of cAMP was observed with both isoprenaline 
and the mAbs on the CHO.K1 parental cell line that was not 
transfected with turkey β
1
AR (data not shown), although the 
effects were very small compared with the response in cells stably 
transfected with β
1
AR. In both cases, this effect could be blocked 
by propranolol suggesting that the background response was 
likely mediated by endogenous β-adrenergic receptors in this cell 
line.
MAb1 and MAb3 were selected for pharmacological 
characterization based on their contrasting physical properties. 
The EC
50
 for MAb1 activation of the wild-type β
1
AR receptor 
in this assay using stable transfected cells was in the range of 
0.1–0.36 nM in the absence of propranolol compared with 
3.9–33 nM in the presence of 10 µM propranolol (Fig. 3B), 
whereas MAb3 was not significantly propranolol sensitive 
(Fig. 3C). However, we observed a significant decrease in the 
maximum response to MAb3 in the presence of propranolol. 
This is consistent with non-competitive antagonism and would 
be expected if propranolol and MAb3 are binding to different 
sites on the receptor.
Homology between turkey and human in ECL2 is the same 
as between turkey and mouse. Receptor sequence alignment 
between turkey, mouse and human β
1
AR is shown in Figure 4 
with corresponding ECL homologies indicated beneath. To 
determine whether the antibodies would cross-react with human 
β
1
AR, the cAMP assay was repeated on CHO cells transiently 
transfected with human wild-type β
1
AR. All the antibodies 
that were able to activate the turkey receptor were also found 
to stimulate signaling of the cAMP pathway via the human 
receptor. MAb1 and MAb3 in particular showed similar agonist 
responses at both human and turkey WT receptors, with EC
50
 
values of 10.75 nM and 1.93 nM at the turkey receptor and 9.4 
nM and 3.6 nM at the human receptor for MAb1 and MAb3, 
respectively (Fig. 3D).
The functional properties associated with antibody format 
were also evaluated using fragments produced by pepsin [F(ab’)
2
] 
or papain (Fab) enzymatic digestion. It was observed that the 
dimeric structure of the F(ab’)
2
 format maintained similar agonist 
activity to the intact mAb from which it was derived (Fig. 3E and 
3F). However, agonism of the receptor was greatly reduced for 
the monomeric Fab format, which had a reduced Emax, whereas 
a similar Emax (EC
50
 = 62.9 nM and 27.3 nM) was observed 
for the corresponding F(ab’)
2
 of MAb1 and MAb3 despite a 
reduction (half-log to a log) in potency. On further investigation, 
it was confirmed that the Fab is capable of completely blocking 
the agonist activity of its corresponding IgG.
Effects of mAbs on the modulation of cAMP response to 
isoprenaline
In addition, we investigated the modulation of cAMP response 
by the mAbs to isoprenaline. Thus, concentration response curves 
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were evaluated in the cAMP assay for isoprenaline where the 
potency of isoprenaline could be reduced in the presence of 10 
µM propranolol. For the example shown in Figure 3B and C, the 
EC
50
 values were 30.6 nM and 103.8 µM, respectively. Similarly, 
concentration response curves for isoprenaline were investigated 
in the absence and presence of MAb1 and MAb3. There was no 
significant effect of MAb1 on the potency of isoprenaline, 
EC
50
 = 32.1 nM vs. 28.6 nM (Fig. 3B). On the other hand, 
MAb3 reduced the potency of isoprenaline 10-fold, to EC
50
 = 
224.9 nM (Fig. 3C). In contrast there was no significant effect 
on either isoprenaline potency or efficacy in the presence of either 
Fab (data not shown), suggesting that it is the dimeric format of 
Figure 3. For figure legend, see page 252.
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MAb1 and MAb3 that causes the conformational change leading 
to an effect on the functional activity of isoprenaline.
Effects of the β
1
AR mAbs on β-arrestin recruitment
Agonist activation of β
1
AR results in the recruitment of 
β-arrestin to the receptor as demonstrated in the enzyme 
fragment complementation assay. The EC
50
 for isoprenaline in 
this assay was found to be in the range 63.9 nM ± 15.8 (Fig. 3G). 
In contrast, MAb1 and MAb3, which potently stimulated G 
protein signaling to increase cAMP levels, had no effect in the 
β-arrestin recruitment assay at concentrations up to 1000-fold 
greater than their respective EC
50
 values in the cAMP assay.
Effects of the β
1
AR mAbs on radioligand competition 
binding
Inhibition binding studies using the orthosteric antagonist 
[3H] dihydroalprenolol (DHA) were used to characterize the 
interactions of both mAbs separately and in combination with 
the β
1
AR agonist isoprenaline and the antagonist propranolol 
at the turkey WT β
1
AR receptor. Both isoprenaline and 
propraanolol fully inhibited the specific binding of [3H]-DHA 
in a concentration-dependent manner (Fig. 5A) with estimated 
K
I
 values of 100 nM ± 0.14 and 0.8nM ± 0.1, respectively, 
in agreement with previously published data (http://www.
iuphar-db.org/DATABASE/ObjectDisplayForward?objec
tId=28). To determine the interaction of the mAbs with the 
β
1
AR, the effect of both MAb1 and MAb3 on the equilibrium 
binding of [3H]-DHA was determined (Fig. 5B). MAb1 did not 
alter the binding of [3H]-DHA, indicative of neutral cooperativity 
between the binding of the mAb and radioligand (α = 1). 
MAb3 caused a modest, concentration-dependent inhibition of 
[3H]-DHA binding, yielding estimates of K
B
 = 16 nM and α = 0.3, 
indicative of weak negative allosteric modulation. It is important 
to note that this value concerns the nature of the interaction / 
analysis. The affinity (and cooperativity) estimate from the 
data provided reflect the fact that the inhibition is incomplete 
because the interaction is allosteric rather than competitive. 
Similar observations have been reported for other receptor-ligand 
interactions, such as M1 receptor allosteric modulation.26
Subsequent experiments were designed to assess the effect 
of these mAbs on the affinity of isoprenaline and propranolol 
binding to the receptor. Increasing concentrations of MAb1 
yielded a concentration-independent increase in the affinity of 
isoprenaline (P < 0.01; F-test; Fig. 5C and D). As such, these data 
could not be modeled using the extended ternary complex model, 
but instead the simple single site model employed suggested 
that isoprenaline affinity was increased 5-fold in the presence 
of MAb1 (α ≈ 5). Similar concentrations of MAb1 had no 
significant effect on the affinity of propranolol (P = 0.18; F-test), 
indicative of neutral cooperativity (α = 1) for this antibody. Due 
to the lack of concentration-dependent effects on the binding of 
any of the ligands, it was impossible to estimate the affinity of 
MAb1 for the β
1
AR.
In contrast, increasing concentrations of MAb3 yielded a 
progressive leftward shift for both the isoprenaline and propranolol 
binding curves, suggesting that MAb3 induced concentration-
dependent increases in their affinity. Analysis according to the 
extended ternary complex model yielded an estimate of the 
positive cooperativity between MAb3 and isoprenaline (α = 9) 
and propranolol (α = 3; Fig. 5E and F). As expected, the weak 
negative allosteric modulation of MAb3 with respect to [3H]-DHA 
was reflected by a modest, concentration-dependent reduction in 
specific [3H]-DHA binding (Fig. 5E and F).
Antibody-receptor interaction
MAb3 was prioritized for evaluation by fSEC analysis to test 
the potential effect on receptor dimerization given that this mAb 
binds to ECL2. These experimental conditions were repeated and 
extended using the corresponding Fab. Both antibody formats 
altered the fSEC profile of β
1
AR, indicating that antibody-
antigen complexes had formed and were intact in the detergent.
Size determination demonstrated that β
1
AR alone elutes as 
a 110 kDa species (as a GFP fusion molecule), whereas β
1
AR 
+ MAb3 elutes as a 390 kDa species and β
1
AR+Fab3 elutes as 
a 170 kDa species after subtraction of the molecular weight of 
the antibody format (Fig. 6A). These data suggests that MAb3 
causes a size change consistent with an IgG binding two receptor 
molecules and are suggestive of receptor dimerization. As 
expected, Fab3 binds to a single β
1
AR molecule based on the 
changes on protein size. It should be noted that any antibody 
aggregation would change the molecular weight of the complex, 
Figure 3 (See previous page). (A) Functional characterization of mAbs evaluating the stimulation of cAMp production through the turkey wild-type 
β1AR receptor for MAbs 1–5 alongside isoprenaline and anti-FLAG (isotype control) using the cell-based HitHunter cAMp assay where data points repre-
sent the mean of triplicate experiments measuring relative luminescence units (RLU). (B) the HitHunter cAMp assay was performed in the absence and 
presence of 10 µM propranolol to evaluate the effect of this antagonist ligand on mAb potency. Data points have been normalized and represent the 
mean of triplicate data samples. Where a) the potency of isoprenaline was reduced (eC50 from 30.6nM to 103.8µM) in the presence of 10µM propranolol; 
b) the MAb1 eC50 value is reduced from 0.1 nM to 32.9 nM; and c) dose response curves for isoprenaline to evaluate potential for modulating agonist 
response were also investigated in the absence and presence 500nM MAb1. (C) the HitHunter cAMp assay was performed in the absence and presence 
of 10 µM propranolol to evaluate the effect of this antagonist ligand on mAb potency. Data points have been normalized and represent the mean of 
triplicate data samples. Where a) the potency of isoprenaline was reduced (eC50 from 30.6nM to 103.8µM) in the presence of 10µM propranolol; b) the 
MAb3 eC50 is unaffected; and c) dose response curves for isoprenaline to evaluate potential for modulating agonist response were also investigated in 
the absence and presence 500nM MAb3. (D) cAMp stimulation of both human (solid black circle) and turkey (solid black square) wild-type β1AR recep-
tors by two antibodies, thus demonstrating species cross-reactivity by showing similar functional potencies. Data point values have been normalized 
representing the mean of triplicate samples. (E and F). Antibody fragments for MAb1 and MAb3 were generated and evaluated for functional properties 
using the cAMp HitHunter cell based assay where (a) the antibody format is indicated by the denotation of IgG, F(ab’)2 and Fab. Data point values have 
been normalized representing the mean of triplicate samples; and (b) the Fab fragment antagonizes its corresponding IgG in the cell-based HitHunter 
cAMp assay; Data point values have been normalized representing the mean of triplicate samples. (G) β-arrestin independent cAMp signaling. Having 
demonstrated that the mAbs were also cross-reactive with the human wild- type β1AR receptor, dose response curves for the anti-β1AR mAbs were then 
assessed alongside an irrelevant antibody (anti-FLAG) in the DiscoverX pathHunter kit that utilizes frozen cell-division arrested cells stably transfected 
with both wild type human β1AR and β-arrestin. Samples were evaluated in triplicate.
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Figure 4. the amino acid sequences for eCL1, eCL2, and eCL3 for turkey, mouse and human 
β1AR are highlighted in blue, black and pink respectively. the corresponding % homology is 
shown below for comparison between these different species.
which in turn would lead to changes in the 
elution time of the receptor. However, it is also 
unlikely that aggregated antibody would be 
able to still bind receptor. Dimerization can be 
caused by bivalent binding, i.e., to an epitope 
on each receptor molecule within a dimer (or 
oligomer). This is distinct from dimer-specific 
binding where a novel binding site (or neo-
epitope) is created by the interacting receptor 
monomers. Subsequently, Fab3 was prioritized 
for Biacore affinity measurement, which 
indicated a KD of 43nM for Fab3 (Fig. 6B).
In vivo effects of β
1
AR MAb3
MAb3 was selected for evaluation of 
its effects in a rat cardiovascular model that assesses heart 
rate and blood pressure because this antibody expressed well, 
demonstrated a good level of receptor activation in the cell-based 
assays, and we were able to map its corresponding epitope to 
ECL2. Given the level of homology between inter-species β
1
AR 
ECL sequences and the observed in vitro activity seen at turkey 
and human receptors, we would anticipate activity at the rat 
receptor. Cardiovascular responses to the MAb3 and its IgG1 
isotype control are shown in Figure 7. Administration of MAb3 
caused no significant change in blood pressure, but a significant 
(P < 0.05, Friedman’s test) increase in heart rate starting 20 
min after the onset of administration and persisting for the 
remainder of the experimental period, whereas administration 
of the corresponding IgG1 isotype control caused no significant 
change in blood pressure or heart rate. Hence, the integrated 
(0–240 min) increase in heart rate was significantly (P < 0.05, 
Mann-Whitney U-test) greater in the group given MAb3 than 
in the IgG1 isotype control group. While no significant change 
in systemic arterial blood pressure was observed, it is nonetheless 
possible that there were peripheral microvascular effects of the 
antibody. The observed tachycardic effect with MAb3 would be 
consistent with β
1
AR agonism.
Discussion
A thermostabilized β
1
AR has been used to generate functional 
anti-β
1
AR mAbs following in vivo immunization that employed 
a strategy of DNA priming followed by protein boosting. A 
differentiating feature of the StaR platform is that the mutations 
can influence the stability and conformation of the protein 
providing correctly folded antigen for antibody discovery. The 
stabilizing mutations are conformation specific depending on 
the pharmacology of the ligand used StaR generation and can be 
identified in regions across the receptor, but mainly affect helix-
to-helix interactions. It is important to note that for antibody 
generation, we deliberately avoid incorporating mutations in the 
extracellular domains of the N terminus and the ECLs.
Five stable hybridomas that demonstrated specific binding for 
β
1
AR StaR protein were identified and four of these hybridoma 
clones produced mAbs that exhibited functional activity as 
observed in cAMP signaling assays. MAb5 did not exhibit 
functional properties in either the cAMP signaling assay or the 
β-arrestin assay and was not progressed further in this study. At 
least two of the anti-β
1
AR mAbs (MAb3 and MAb4) map to 
an epitope on ECL2. These mAbs could either represent two 
difference sequences that bind to the same epitope or that the 
mAbs themselves are two clones of the same antibody. In fact, 
restriction fragmentation confirmed that these were different 
mAbs. It has been reported that autoantibodies mapping to the 
β
1
AR ECL2 are highly pathogenic in a variety of cardiomyopathy 
conditions, inducing aortic dysfunction and ventricular 
arrhythmia,27,28 thought to be mediated by pro-apoptotic 
effects.29 Additionally, β
1
AR autoantibodies have been described 
as potent agonists of the ERK1/2 pathway30 and increase tumor 
necrosis factor secretion in RAW264.7 macrophages, which is 
thought to be PKA-dependent.31 A review summarizing the role 
and mechanisms of cardiac autoantibodies in cardiomyopathy 
demonstrates that β
1
AR autoantibodies play a significant role 
in the pathophysiology of heart failure.32 Recently, the cyclic 
peptide COR1, designed to block anti-β
1
AR autoantibodies by 
mimicking the tertiary structure of ECL2, has shown efficacy 
in a rat model of autoimmune cardiomyopathy.33 Subsequently, a 
Phase 1 clinical study has demonstrated safety in humans and 
good pharmacokinetic properties (NCT 01043146).34
A number of groups have described a critical role for ECL2 
in the binding of orthosteric and allosteric ligands to GPCRs,35 
including ligand activation of the C5a receptor36 and residues 
that contribute to ligand specificity between the muscarinic 
M
2
 and M
5
 receptor subtypes.37 It is also thought that receptor 
antibodies generated by immunization can act in a different way 
to autoantibodies isolated from patient sera.38 The agonist activity 
attributed to β
1
AR autoantibodies is less prone to induce receptor 
desensitization than classical agonist ligands39 and, when bound 
at the same time as natural agonists, the autoantibodies are able to 
modulate the receptor response.38
β
1
AR autoantibodies have been postulated to bind to 
conformational epitopes that may represent a domain separate 
to the ligand binding pocket,43 and this domain is thought to 
be part of ECL2. Although ECLs are not involved directly in 
agonist binding, it has been proposed that ECL2 in the form of 
a helix reaches into the ligand binding pocket and can contact 
the ligand.40,41 Disulfide bonds essential for maintaining this 
domain out of the ligand binding pocket, which enables natural 
ligand binding,40 have been hypothesized to be sited within these 
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antibody epitopes.42 Hence, conformational changes to this loop 
would be anticipated to affect receptor activity.
The mode of action identified here for MAb3, which also 
interacts with ECL2, may be due to the ability of the antibody to 
stabilize an agonist conformation or through an ability to prevent 
ECL2 from interacting with the ligand binding site. Modulation 
of receptor agonism has previously been proposed for stimulatory 
autoantibodies against 
ECL2, and the hypothesis 
is based on the observation 
that autoantibodies decrease 
not only ligand affinity, but 
also the maximal capacity 
of equilibrium radioligand 
binding to the receptor in a 
dose-dependent fashion.43 A 
recent review has documented 
progress made in determining 
the role of extracellular loops 
in ligand binding and the 
subsequent activation of 
GPCRs,41 drawing upon the 
advances made in GPCR crystal 
structure determination and 
associated molecular modeling 
studies that suggest ECL2 can 
play a role in ligand selectivity 
within a diverse range of 
GPCRs, such as the muscarinic 
receptors, β
1
AR and β
2
AR, A
2A
 
receptor and CXCR4. Finally, 
the cAMP signaling data 
obtained in our study correlates 
with other observations that 
β
1
AR autoantibodies and 
isoprenaline-mediated effects 
are not identical with regard 
to the maximum increase 
in current amplitude for rat 
ventricular cardiomyocytes.39
It is evident from our results 
that the interaction of MAb1 
with β
1
AR is very different 
from that of MAb3. MAb1 
does not change the affinity of 
[3H]-DHA, but exerts a positive 
effect on isoprenaline binding 
by a factor of 5-fold, suggesting 
a positive allosteric modulation 
of isoprenaline binding, 
although surprisingly there was 
no significant effect of MAb1 
on the potency of isoprenaline 
(EC
50
 = 32.1 nM vs. 28.6 nM). 
MAb1 was neutral with regard 
to propranolol in the binding 
affinity assay. Given that MAb1 
does not directly affect the binding of propranolol, the blocking 
effects of propranolol on antibody activation in the cAMP 
assay may be mediated by changes in the receptor’s ability to 
be activated in the presence of antagonist. In addition, western 
blot analysis suggests that MAb1 is a conformationally sensitive 
antibody.
Figure 5. Radioligand competition binding evaluations for the effect of (A) isoprenaline and propranolol and 
(B) MAb1 and MAb3 on specific [3H]-DHA binding to HeK293-β1AR (wild-type receptor) cell membranes. Data 
points represent the mean of two independent experiments. Inhibition of specific [3H]-DHA binding by (C) 
isoprenaline and (D) propranolol in the presence of increasing concentrations of MAb1 to HeK293-β1AR (wild-
type receptor) cell membranes. Data points represent the mean of two independent experiments. Inhibition 
of [3H]-DHA specific binding by (E) isoprenaline and (F) propranolol in the presence of increasing concentra-
tions of MAb3 to HeK293-β1AR (wild-type receptor) cell membranes. Data points represent the mean of two 
independent experiments (where each data point was performed in triplicate).
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Figure 6. (A) evaluation of antibody-receptor interaction by fSeC analy-
sis using a β1AR-GFp fusion construct. the data indicates that MAb3 
(red trace) changes the motility of the receptor (blue trace) where the 
size change is consistent with an IgG binding two receptor molecules. 
Similarly, an additive size change is observed for Fab3 (green trace) rep-
resenting a Fab fragment binding one receptor molecule. (B) Affinity 
evaluation of antibody-receptor interaction for the corresponding Fab 
fragment of MAb3 by SpR analysis.
Figure 7. In vivo assessment of MAb3-β1AR using a freely-moving con-
scious rat model for the evaluation of cardiovascular responses. open 
circles represent the isotype control at 3 mg/kg and filled circles repre-
sent MAb3 at 3 mg/kg. the increases in heart rate and blood pressure 
have been plotted over a time course of 4 h. Values are mean and verti-
cal bars indicate SeM, n = 6. * Friedman’s test, P < 0.05. # Mann-Whitney 
test, P < 0.05.
In contrast, MAb3 appears to act as an agonist. The antibody 
could bind in the same position (orthosteric) as isoprenaline, or 
that the antibody may bind to a distinct location on the receptor 
(allosteric site), creating a conformational change that affects 
the orthosteric ligand binding pocket. The latter mechanism is 
more likely because MAb3 caused a 10-fold reduction (EC
50
 = 
224.9nM) in the potency of isoprenaline, despite significantly 
enhancing the binding affinity of isoprenaline. A similar example 
has been reported for small molecule allosteric modulators of 
cannabinoid receptors where opposite effects were described 
for agonist binding vs. agonist function. Although this seems 
counter-intuitive, these allosteric modulators had differential 
effects on affinity and potency. These small molecule ligands 
increased binding of the radioligand [3H]-CP55,940 while acting 
as insurmountable antagonists in function at the CB
1
 receptor, 
i.e., a reduction in signaling efficiency,44 and even other, more 
complex states of allosteric modulation have been described
.
45,46
None of the mAbs in this study had any effect in the β-arrestin 
recruitment assay at concentrations up to 1000-fold the EC
50
 
in the cAMP assay. There are, however, many examples of 
differences between the degree of receptor activation through G 
proteins and β-arrestin recruitment. This dissociation between 
G protein activation (leading to cAMP signaling) and β-arrestin 
recruitment is known as biased agonism47 and suggests that the 
mAbs stabilize a different active conformation to isoprenaline, 
which can signal down both pathways. Only one other example of a 
biased agonist mAb has been described to our knowledge, namely, 
an anti-mGluR7 mAb that triggers receptor internalisation48 via 
a pertussis toxin-insensitive pathway that does not involve Gα
i
 
and is not dependent on the cAMP signaling pathway. The mAb 
divalent format was required for internalisation, prompting the 
authors to propose that the IgG caused a conformational change 
involving receptor dimers thereby inducing the internalisation 
process.
GPCR dimerization can be associated with changes in ligand 
binding affinity, through inter-receptor positive or negative 
cooperativity. The β
1
AR mAbs described here are all divalent, 
providing the possibility for receptor oligomerisation and, in 
the case of MAb3, can alter the potency of the agonist ligand. 
Epitope binning via pair-wise competition and peptide mapping 
indicate that MAb3 binds to ECL2, but it binds to a completely 
different epitope from MAb1. MAb1 itself is conformationally 
sensitive as determined by its lack of binding to receptor protein 
in Western analysis, where receptor protein will be denatured 
and only linear epitopes exposed. It is possible that the β
1
AR 
mAbs are able to stabilize conformational states associated with 
dimeric forms of the receptor in a similar manner as has been 
hypothesized for the angiotensin AT1 receptor.18
Although it is known that SDF-1 triggers CXCR4 
dimerization, activating the JAK/STAT pathway,49 and MCP-1 
induces functional responses through dimerization of CCR2,50 
there is mixed evidence in the literature that receptor dimerization 
is linked to activation of GPCRs. Receptor dimerization has been 
described as a critical step in chemokine signaling.51 The bivalent 
format of mAbs allows for the potential to induce receptor 
dimerization, but this does not necessarily lead to a functional 
response, e.g., anti-CCR5 mAb CCR5–02. This mAb does 
not compete for ligand binding to the receptor, whereas the 
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anti-CCR2 mAb CCR2–02 produces an agonist response and 
does compete with ligand binding to the receptor.52
In conclusion, four unique agonist mAbs have been isolated 
that bind to different epitopes on the limited extracellular 
surface of β
1
AR and appear to possess different mechanisms of 
action relating to the nature of interaction with the receptor. 
Further study would be necessary to elucidate these differences 
in antibody-receptor interactions, such as co-crystallization 
studies using the corresponding Fabs of MAb1 and MAb3, which 
could shed further light on the role of ECL2 in ligand-induced 
activation of GPCRs. By interrogating the interaction of these 
activating antibodies with the receptor, valuable insights into the 
structure-function of GPCR activation would be gained.
Rat and mouse ECL homology are 100% identical, hence 
cross-reactivity of the murine β
1
AR mAbs with the rat receptor is 
expected. In vivo studies of β
1
AR suggest the amplitude in cellular 
responses can be used to predict the cardiovascular properties of 
small molecule β-blockers,53 where isoprenaline is used as a small 
molecule positive control. As with the cAMP assay, we observe a 
response from a therapeutically relevant dose of antibody that is 
lower than that of the full isoprenaline response. It was notable that 
there was a tachycardic effect following administration of MAb3 
to conscious rats, which could be explained by β
1
AR agonism, but 
this was not associated with any significant change in systemic 
arterial blood pressure. β
1
AR agonism might have been expected 
to have caused a rise in blood pressure due to concurrent positive 
inotropic and chronotropic effects. Hence, the lack of change in 
blood pressure might suggest either that the cardiac effects were 
insufficient to increase cardiac output or there were underlying, 
opposing, regional vascular effects to offset any change in blood 
pressure. It would, therefore, be desirable to further investigate 
regional hemodynamic effects of this anti-β
1
AR mAb activity in 
vivo, in order to more fully understand the cardiovascular effects 
observed at this therapeutically-relevant dose.
Unlike other antigen production methods, DNA 
immunization has the unique advantage that the antigen is 
produced in the native environment of the host animal. This 
maximizes the likelihood of the protein forming its native 
structure via intracellular synthesis with correct post-translational 
modifications, three-dimensional folding and trafficking to the 
cell surface with correct presentation. However, workers in the 
field report that it may only produce low levels of antibodies 
when using the WT receptor, which can impede the success of 
identifying a therapeutic. The method we used here employs the 
Gene Gun where DNA delivery is via the bombardment of the 
skin with DNA-coated microparticles. We followed this with a 
short protein boost prior to the fusion process, thereby reserving 
the usage of recombinant StaR protein and enabling a less protein 
resource-intensive route to identifying functional antibodies.
In this study, the use of a thermostabilized receptor in both 
DNA and protein immunogen format has demonstrated the 
ability to generate functionally active mAbs to a GPCR, where 
β
1
AR presents a far smaller extracellular surface area than other 
GPCRs, such as CXCR4, for which there are a number of mAbs 
in development (and where the mAbs are generally antagonizing 
the receptor by targeting the N terminus). Despite only 
identifying five stable hybridomas, we demonstrated that four of 
these mAbs exhibit agonist activity, suggesting that the quality 
of the GPCR antigen not only has to be biochemically pure, but 
also biophysically pure, i.e., correctly folded and enriched for 
biologically relevant epitopes.
Targeting peptide receptors and other GPCRs with a large 
ligand binding domain, such as chemokine and Family B 
receptors, with an antibody is a useful alternative approach to 
generating small molecule drugs. A recent example of this has 
been the reporting of antagonist mAbs directed to the glucose-
dependent insulinotropic polypeptide receptor (GIP).54 Similarly, 
orphan receptors (for which there are no known ligands) and 
GPCRs with emerging biology (such as the adhesion subfamilies) 
present a challenge in drug development. Attempts to identify 
small molecule agonists or antagonists for these generally fail; 
however, a functional mAb provides an alternative approach to 
identifying drugs to such targets. The generation of purified StaR 
proteins and the corresponding StaR cDNA for immunization is 
an emerging technology that may provide the means to develop 
therapeutic mAbs to clinically important GPCR targets.55 The 
study presented here has attained initial proof-of-concept, and 
provided valuable initial insight into the mechanism of action 
of these mAbs that show different interactions with the receptor 
as reflected by the varied pharmacological profiles mapping to 
different epitopes.
Materials and Methods
β 
1
AR StaR protein
The thermostabilized turkey (Meleagris gallopavo) β
1
AR StaR, 
also called β
1
AR-m23,15 was used as the antigen. This stabilized 
receptor contains eight amino acid changes (C116L increased 
expression; C358A at the C terminus of Helix 8 removed 
palmitoylation and were previously included to help protein 
crystallization; and R68S, M90V, Y227A, A282L, F327A and 
F338M were added to increase the thermostability). The receptor 
was expressed in insect cells using the baculovirus system and 
purified in 0.1% (v/v) decylmaltoside (Anatrace) with 0.1 mM 
alprenolol (Sigma-Aldrich) bound as previously described.16
Immunization and isolation of mAbs
A β
1
AR StaR cDNA construct that included the full-length 
native N-terminus of β
1
AR was prepared. This was used for 
genetic immunization of 3 female balb/c mice with Aldevron 
Freiburg’s proprietary Gene Gun system (Aldevron Freiburg 
GmbH, formerly GENOVAC GmbH), implementing a primary 
challenge of cDNA, followed by 3–6 boosts of cDNA and a 
further boosting with purified β
1
AR StaR protein. The strength 
of the β
1
AR immune response was monitored by flow cytometry 
and ELISA analysis of the sera. All animals gave significant 
responses and were sacrificed after a minimum of 100 d. Lymph 
nodes were harvested and isolated lymphocytes used to generate 
hybridoma fusion clones with mouse myeloma Sp2 cells using 
standard hybridoma methods. 1000 clones were picked from 
one fusion. Hybridoma supernatants were screened for specific 
binding to β
1
AR by ELISA and to the extracellular domains of 
the receptor by flow cytometry analysis. Once stable hybridoma 
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cell lines had been established and monoclonality confirmed, the 
resulting expressed IgGs were also validated by flow cytometry 
analysis, and progressed to small-scale IgG production and isotype 
identification by an ELISA-based method using the Biozol isotype 
kit for mice (Southern Biotech).
Antibody specificity ELISA
β
1
AR StaR protein was immobilized via capture of the 
C-terminal His6 tag to nickel-coated 96-well Nunc Immobilizer 
plates (Thermo Scientific). Plates were coated with 5 µg/ml 
antigen solubilised in 0.1% (v/v) DM (Anatrace) and 0.1 mM 
alprenolol (Sigma-Aldrich). Serial dilutions of mouse sera or 
purified IgG were prepared and evaluated for antibody binding. 
Bound antibody was detected with goat anti-mouse horseradish 
peroxidise (HRP)-conjugate (Cell Signaling Technology) using 
the TMB (3,3′,5,5′-Tetramethylbenzidine) liquid substrate 
system (Sigma-Aldrich). The absorbance was read at 655 nm. To 
determine mAb specificity, binding to β
1
AR was compared with 
that of A
1
 StaR (adenosine A
1
 receptor), A
2A
 StaR (Adenosine A
2A
 
receptor) and an unrelated StaR (Orexin 1). The unrelated Orexin 
1 StaR also provided a control for potential binding to the His-
tag. The presence of antigen successfully coated to the plate well 
was confirmed using a mouse anti-Penta His tag mAb (Qiagen).
Western blotting
β
1
AR StaR protein was diluted to 14 µg/ml and 22 µl of the 
sample mixed with 2µl 1 M DTT and 8 µl 4x LDS sample buffer 
(Expedeon Protein Solutions Ltd) to load 0.3 µg protein per well 
and subjected to electrophoresis on a 4–20% Tris-Glycine SDS 
PAGE Novex pre-cast gel (InVitrogen). Western blot transfers 
were made onto nitrocellulose membrane (Invitrogen) and probed 
with monoclonal IgG at 10 µg/ml. Bound antibody was detected 
with secondary anti-mouse HRP conjugate (Sigma-Aldrich) and 
the ECL detection system (Thermo Scientific) with exposure of 
Amersham Hyperfilm ECL autoradiograph film (GE Healthcare) 
to the nitrocellulose membrane.
Flow cytometry analysis to identify hybridoma clones of 
interest
The level of immune response was evaluated for binding to 
β
1
AR-expressing cells using flow cytometry and determination of 
the sera titer. Binding for the resulting mAbs was also confirmed 
in this manner. Mouse anti-sera or mAbs binding cells expressing 
β
1
AR StaR was detected using goat anti-mouse PE conjugate 
(BD Bioscience) and the background/ specificity evaluated on 
cells transiently transfected with an irrelevant cDNA. This was 
compared with the binding profile of the pre-immune bleed 
to monitor the strength of immune response. The hybridoma 
fusion performed for this study focused on identifying antibodies 
that bound to extracellular epitopes, hence a cell-based ELISA 
(developed in-house at Aldevron) was employed for sample testing 
and flow cytometry was used for further confirmation of positive 
hybridoma supernatants.
Measurement of cAMP stimulation using the HitHunter 
XS+ cAMP assay
The DiscoveRX HitHunter assay kit (#90–0075L) is a 
sensitive detection assay for the stimulation of the secondary 
messenger cAMP.56 A CHO cell line stably expressing the turkey 
wild type β
1
AR was used in the HitHunter assay. In addition, 
to investigate the activity of the antibodies against the human 
receptor, CHO cells were transiently transfected with human 
wild type β
1
AR cloned into pcDNA3.1 mammalian expression 
vector (gift from Dr Chris Tate, Laboratory of Molecular 
Biology, Cambridge, UK). Cells were plated in 96-well format at 
densities of 4000–25 000 cells/well and cAMP measurement was 
determined according to the recommendations of the DiscoverX 2 
Step Reagent Addition Protocol, with each data point performed 
in triplicate. To investigate the effects of antagonist on antibody 
responses, propranolol (final concentration of 10−4 M) was added 
to the cells for 30 min prior to the addition of ligands/antibody. 
Plates were read on a Polarstar instrument (Omega, BMG Labtech) 
measuring relative luminescence signal in 96-well Costar plates. 
RLU data was plotted against final ligand/IgG concentrations 
and analyzed on GraphPad Prism using a nonlinear fit.
Measurement of β-arrestin recruitment
The DiscoveRX PathHunter eXpress assay kit (#93–0488E2) 
was employed for the evaluation of β-arrestin recruitment using 
cells stably transfected with both wild type human β
1
AR and 
β-arrestin (#93–0446E1). This assay measures receptor activation 
via G-protein dependent and independent signaling because 
GPCR mediated β-arrestin signaling may occur regardless of 
G-protein coupling. It is possible to identify agonism, antagonism 
and allosteric modulation if the receptor recruits β-arrestin. 
Cells stably transfected with both wild type human β
1
AR and 
β-arrestin were used for the assay. The assay was performed 
according to the manufacturer’s instructions.57 Isoprenaline 
was used as a positive control and anti-FLAG mouse mAb was 
used for the negative control, with each data point performed in 
triplicate. Luminescence was read on a Polarstar plate reader and 
data analyzed using GraphPad Prism.
Cell membrane preparation for radioligand binding assays
Membranes were prepared from β
1
AR transiently-expressing 
HEK293 cells. Cells were transfected with β
1
AR cDNA using 
Genejuice (Merck Biosciences). After 48 h, cells were harvested 
by trypsin, centrifuged (350 g, 5 min) and the resulting cell 
pellet stored at −80° C until required. To prepare membranes, 
the pellet was resuspended in 20 ml buffer (20 mM HEPES, 
10 mM EDTA, pH 7.4) and homogenized using an Ultra-Turrax 
homogenizer for 10 s at the maximum setting. The homogenate 
was centrifuged (350 g for 15 min), supernatant collected, 
stored on ice and the pellet resuspended in 20 ml buffer. This 
process was repeated twice prior to centrifugation at 40 000 g for 
45 min. The resultant pellet was resuspended in 20 ml of storage 
buffer (20 mM HEPES, 0.1 mM EDTA pH 7.4) and protein 
content determined by bicinchoninic acid (BCA) analysis. The 
homogenate was diluted to 2 mg/ml aliquots and stored at -80 °C 
until required.
Radioligand binding studies
Radioligand binding studies with [3H]-DHA were used 
to determine the effects of antibodies on the binding of 
agonist and antagonist ligands to the receptor. HEK293-
β
1
AR cell membranes (5 μg/well) were incubated with ligand 
(concentration range) in Kreb’s buffer (118 mM NaCl, 
8.5 mM HEPES, 4.7 mM KCl, 4 mM NaHCO
3
, 1.3 mM CaCl
2
, 
1.2 mM MgSO
4
, 1.2 mM KH
2
PO
4
, 11 mM glucose; pH 7.4) 
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for 2 h at 25° C. Non-specific binding was defined by 0.1 mM 
alprenolol. Saturation binding data were modeled using a single 
site hyperbolic equation to determine the ligand K
D
. The K
D
 value 
of [3H]-DHA was determined to be 3.3 nM ± 0.34 (n = 2) and 
was used in subsequent competition studies.
Competition binding studies
For competition binding studies, 250 μl Kreb’s buffer 
containing [3H]-DHA (7 nM) and HEK293-β
1
AR cell 
membranes (5 μg/well) were incubated for 4 h (25° C) with a 
range of concentrations of either propranolol, isoprenaline or 
mAb in the presence or absence of multiple, fixed concentrations 
of mAb or Fabs. The reaction was terminated by rapid filtration 
through 96-well GF/B filter plates pre-soaked in 0.1% (v/v) 
polyethyleneimine solution (PEI) using a Tomtec liquid handler 
and washed with ddH
2
O. Plates were left to dry prior to addition 
of Safe Scint liquid scintillant (LabLogic). Plates were sealed and 
bound radioactivity measured using a Microbeta (PerkinElmer). 
Data was normalized to % specific binding for analysis. For 
competition by isoprenaline and propranolol, data were modeled 
using a single site binding model. IC
50
 values were converted to 
K
B
 values using the K
D
 value determined by saturation binding.58
To determine the effect of mAbs alone against [3H]-DHA 
binding, data were modeled with an allosteric ternary complex 
model59,60 allowing the determination of α, the cooperativity 
factor, governing the interaction between [3H]-DHA and the 
mAb. For studies examining the effect of MAb3 binding on 
the affinity of propranolol or isoprenaline, data were modeled 
according to an extended ternary complex model that describes 
the interaction between two orthosteric ligands (i.e., [3H]-DHA 
and propranolol or isoprenaline) and a putative allosteric ligand 
(MAb3). Due to the very limited effect of MAb1 on the binding 
of ligands, curves for this study were modeled according to the 
single site model and the resultant K
B
 values compared by F-test 
for significance.
Antibody epitope mapping
Epitope binning by surface plasmon resonance
Epitope mapping using pair-wise competition was performed 
using a Biacore T200 instrument and NTA sensor chip (GE 
Healthcare). The assay was performed in PBS, 0.1% (v/v) DM, 
0.1 mM alprenolol, 0.05 mM EDTA pH 7.4 at 25° C. Each assay 
cycle began with the capture of β
1
AR StaR protein (0.5 µM, 1 
min injection) followed by the injection of the first antibody, 
followed by the second antibody (0.5 µM, 5 min each). Finally, 
the chip surface was regenerated with 1.0 M imidazole (Sigma-
Aldrich), 0.1% (v/v) DM (15 min).
Peptide mapping
Peptides were synthesized that encode the extracellular domains 
of turkey β
1
AR, including the N terminus (Nt) and the first 
(ECL1), second (ECL2) and third (ECL3) extracellular loops. To 
orientate the peptide, a C-terminal Cys residue was added where 
it was not already present in the native sequence. Two peptides 
were synthesized that represented the proximal and distal regions 
of extracellular loop 2 (ECL2a and ECL2b) using the position 
of the first Cys residue to segment the domain. The sequences 
were as follows: Nt, MGDGWLPPDC GPHNRSGGGG 
ATAAPTGSRQ VSAELLSQQC; ECL1, RGTWLWGSFL C; 
ECL2, MHWWRDEDPQ ALKCYQDPGC CDFVTNC; 
ECL2a, MHWWRDEDPQ ALKC; ECL2b, YQDPGCCDFV 
TNC; ECL3, VNVFNRDLVP DC (Cambridge Research 
Biochemicals). Each peptide stock solution, at 10 mg/ml dissolved 
in DMSO (Sigma-Aldrich), was diluted in PBS for immobilization 
to maleimide-activated plate surfaces (Pierce, Thermo Scientific) 
at 50 µg/ml. Plates were incubated overnight at 4° C sealed with 
adhesive microplate lids (Greiner, SLS). Wells were then washed 
with PBS and simultaneously blocked along with underivatized 
sites in PBS/3% (w/v) dried Marvel skimmed milk powder plus 
freshly prepared 100 µg/ml cysteine (Pierce) in PBS for 1–2 h at 
room temperature. The blocking solution was discarded and then 
mAb at 1 µg/ml concentration was added and the plate incubated 
for 1 h at room temperature. The wells were then washed with 
PBS/0.1% (w/v) BSA, 0.05% (v/v) Tween 20 (Sigma-Aldrich) 
and then with PBS. Bound antibody was detected with goat anti-
mouse HRP-conjugate (Cell Signaling Technology) using the 
TMB (3,3′,5,5′-Tetramethylbenzidine) liquid substrate system 
(Sigma-Aldrich) and absorbance read at 655 nm.
Restriction digest analysis to evaluate clone diversity
This method can be used to evaluate antibody gene diversity 
by restriction enzyme fragmentation pattern. Total RNA was 
extracted from hybridoma cells and cDNA of the variable regions 
(V
H
 and V
L
) of the IgG were synthesized and amplified by 
RT-PCR (Genscript) for cloning. To demonstrate gene diversity, 
~1 µg of miniprep DNA from individual colonies for each mAb 
were digested with NlaIV restriction enzyme (NEB) at 37° C for 
3 h, enzyme was heat-inactivated at 65° C for 20 min, then DNA 
fragments were electrophoresed on a 1.5% agarose gel along with 
EZ Load 100 bp Molecular Ruler (Bio-Rad).
SPR analysis of affinity by Biacore
Normally, affinity measurement would involve mAb 
immobilization on the chip followed by antigen injection to 
avoid avidity effects. This proved to be impossible however due 
to high unspecific binding of the receptor to the chip surface. 
The use of NSB reducer (dextran) added to the sample failed to 
prevent problems with unspecific binding. We tried to resolve this 
using a number of different strategies, including that used in the 
identification of a suitable Fab for co-crystallization of A
2A
R,61 
namely, to coat the chip in anti-mouse Fc, capture the antibody 
fragment and then flow the purified receptor over as analyte.
The experiment was run on a Biacore T200 instrument at 
10° C in PBS buffer, pH 7.4, (GE Healthcare) supplied with 0.1 
mM alprenolol, 0.1% DM, 0.05 mM EDTA. The receptor was 
captured on an NTA chip (GE Healthcare) to a level of ca. 1500 
resonance units (RU). The Fab fragments were injected at five 
concentrations in the range 0.25–4 µM in the single cycle format. 
The kinetic constants and equilibrium dissociation constant were 
obtained by fitting the data to 1:1 interaction model using Biacore 
evaluation software (GE Healthcare).
Antibody fragment generation
For Fab fragmentation, 4 mg of protein G purified IgG were 
digested using the papain-based Fab preparation kit (Pierce). The 
procedure was performed according to the instructions provided 
by the supplier. Digestion was performed for 16 h at 37 °C and 
the crude digest was subjected to purification using a Protein 
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A column, removing Fc fragments and undigested material 
(Fc). For F(ab′)
2
 digestion, 2.3 mg protein G purified IgG was 
digested using the Ficin-based F(ab′)
2
 preparation kit (Pierce) 
using the manufacturer’s recommended protocol. Digestion was 
performed for 28 h at 37° C after which undigested material was 
removed using a Protein A column. QC was performed by gel 
electrophoresis prior to protein concentration determination and 
SEC to remove undigested material and excess cysteine with a 
buffer exchange into PBS.
Study of antibody-receptor interactions by fSEC analysis
β
1
AR-m23 receptors C-terminally tagged with EGFP were 
transiently expressed in human HEK293T cells using GeneJuice 
transfection reagent (Merck) according to the manufacturer’s 
guideline. Briefly, for each transfection, 4x106 cells were seeded 
in a 10 cm plate and incubated overnight at 37° C incubator. Next 
day, cells were transfected with 6 μg of plasmid DNA encoding 
β
1
AR-m23-EGFP receptor. After 40 h post-transfection, cells 
were harvested and washed in 10 ml of PBS. The pellets were 
re-suspended in 850 μL of buffer containing 50 mM HEPES 
pH7.5/150 mM NaCl/0.5 mM EDTA supplemented with a 
cocktail of protease inhibitors (Roche Applied Science). The 
total protein content was quantified using BCA assay and 1 mg 
aliquots of the suspension were prepared and pelleted. For each 
fSEC run, pellets were re-suspended in 190 μL of buffer with or 
without 1 μM of antibodies. The samples were incubated at room 
temperature for 1 h to allow antibody binding and following 
equilibration to 4° C, 10 μl of 20% (w/v) n-Dodecyl β-D-
maltoside (DDM) was added for solubilisation. The samples were 
incubated at 4° C for 1 h. The crude lysates were centrifuged at 
50,000 rpm for 30 min prior to application of 50 μl samples to a 
BioSep-SEC-s3000 column (Phenomenex). The flow rate was set 
at 1 ml/min with the total run time of 15 min where the mobile 
phase contained 50 mM HEPES pH7.5/150 mM NaCl/0.5 mM 
EDTA/0.025% DDM. The size quantification was based on the 
calibrations provided by the manufacturer.
In vivo assessment of anti-β
1
AR mAb activity
These studies were conducted at the University of Nottingham 
(UK) under approval from the local ethics committee and 
approved Home Office Project License protocols. Under 
anesthesia (fentanyl and medetomidine, 300 μg/kg i.p. of each, 
supplemented as required), 12 male Sprague-Dawley rats were 
instrumented with intravascular catheters implanted in the 
distal aorta (via the caudal artery) for recording arterial blood 
pressure and heart rate, and in the jugular vein (3 catheters) for 
drug administration. Reversal of anesthesia and postoperative 
analgesia was provided by atipamezole (1 mg/kg s.c.) and 
buprenorphine (0.02 mg/kg s.c.). Experiments commenced 24 
h after the surgical procedure, when the rats were fully conscious 
and freely-moving. Rats were divided into 2 experimental groups 
to evaluate MAb3 at 3 mg/kg vs. IgG1 control at 3 mg/kg. Bolus 
doses were administered in a volume of 0.6 mL at a pump speed of 
1 mL/h, over a period of 36 min. Infusions were administered in 
a volume of 0.4 mL at a pump speed of 0.4 mL/h, over a period of 
60 min. The day following catheterization, continuous recordings 
of cardiovascular variables were made using a customized, 
computer-based system (Instrument Development Engineering 
Evaluation (IDeeQ), Maastricht Instruments), connected to a 
transducer amplifier (Gould model 13-4615-50). Raw data were 
sampled every cardiac cycle and stored to disc for later analysis 
off-line.
Baseline (control) values were taken as the average of the 
10 min period prior to antibody administration; thereafter the 
values represent sequential averages (3 × 10 min, 1 × 30 min, 
3 × 60 min) for the remainder of the recording period. Data were 
analyzed using non-parametric analysis of variance (Friedman 
test) for within-group comparisons, and the Mann-Whitney 
U-test for between-group comparisons, applied to the integrated 
(0–240 min) areas. P < 0.05 was taken as significant.
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